Skip to main content

You are here:

The TOPaz Study

This study aims to investigate if a two year spell of treatment with a drug call Teriparatide, followed by one dose of treatment called Zoledronic Acid can reduce the risk of broken bones (fractures) in Osteogenesis Imperfecta (brittle bone disease). We are comparing this treatment with the usual treatment that patients with OI normally receive.

Type of Study
Phase III/IV
Study Status
Open Recruiting
University of Edinburgh
Principal Investigator
Dr Rachel Crowley